Top

Published in:

01-12-2011 | Case Report

Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome

Authors: Nobuyuki Amemiya, Takashi Takei, Chiari Kojima, Hirohiko Nokiba, Mitsuyo Itabashi, Kosaku Nitta

Published in: Clinical and Experimental Nephrology | Issue 6/2011

Abstract

Treatment with a single dose of rituximab alone induced remission in a patient with relapsed minimal change nephrotic syndrome (MCNS). A 27-year-old man was given corticosteroid (prednisolone; PSL) and cyclosporine (CyA) therapy combined with rituximab for his fifth relapse in 2008. Thereafter, complete remission was achieved and maintained despite eventual discontinuation of the PSL and CyA. In 2010, we treated his sixth relapse with a single dose of rituximab. Complete remission was obtained 32 days later. This is the first report of rituximab monotherapy in the treatment of MCNS.

Cunard R, Kelly CJ. T cells and minimal change disease. J Am Soc Nephrol. 2002;13:1409–11.PubMedCrossRef

François H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2006;49(1):158–61.CrossRef

Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephritic syndrome. Clin Nephrol. 2009;72:69–72.PubMed

Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794–7.PubMedCrossRef

Pescoviz MD, Book BK, Sider RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006;354:1961–3.CrossRef

Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21:1698–700.PubMedCrossRef

Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol. 2007;22:893–8.PubMedCrossRef

Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269–79.PubMedCrossRef

Mansour H, Cheval L, Elalouf JM, Aude JC, Alyanakian MA, Mougenot B, et al. T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int. 2005;67:2168–77.PubMedCrossRef

10.

Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol. 1999;10:529–37.PubMed

11.

Johnson RJ, Hurtado A, Merszei J, Rodriguez-Iturbe B, Feng L. Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am J Kidney Dis. 2003;42:575–81.PubMedCrossRef

Title: Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome
Authors: Nobuyuki Amemiya
Takashi Takei
Chiari Kojima
Hirohiko Nokiba
Mitsuyo Itabashi
Kosaku Nitta
Publication date: 01-12-2011
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 6/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-011-0510-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Accelerated recovery from Candida peritonitis of enteric origin by early surgical drainage in a peritoneal dialysis patient

Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients

Reversible posterior leukoencephalopathy syndrome after blood transfusion in a patient with end-stage renal disease

Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats

Validation of the equations for estimating daily sodium excretion from spot urine in patients with chronic kidney disease

Necrotizing crescentic immunoglobulin A glomerulonephritis in adult-onset Still’s disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials